[go: up one dir, main page]

BRPI0411823A - derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlico - Google Patents

derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlico

Info

Publication number
BRPI0411823A
BRPI0411823A BRPI0411823-5A BRPI0411823A BRPI0411823A BR PI0411823 A BRPI0411823 A BR PI0411823A BR PI0411823 A BRPI0411823 A BR PI0411823A BR PI0411823 A BRPI0411823 A BR PI0411823A
Authority
BR
Brazil
Prior art keywords
hexane
amino
ester derivative
hydrogen atom
group
Prior art date
Application number
BRPI0411823-5A
Other languages
English (en)
Inventor
Akito Yasuhara
Kazunari Sakagami
Hiroshi Ohta
Atsuro Nakazato
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of BRPI0411823A publication Critical patent/BRPI0411823A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

"DERIVADO DE éSTER 2-AMINO-BICICLO¢3.1.0!-HEXANO-2,6-DICARBOXìLICO". A presente invenção refere-se a um medicamento eficaz para o tratamento e prevenção de distúrbios psiquiátricos tais como esquizofrenia, ansiedade e suas doenças relacionadas, depressão, distúrbio bipolar e epilepsia. O medicamento antagoniza a ação dos receptores de glutamato metabotrópico do grupo II e apresenta atividade elevada na administração oral. Um derivado de éster 2-amino-biciclo ¢3.1.0! hexano-2,6-dicarboxílico representado pela fórmula ¢I! ¢em que R¬ 1¬ e R¬ 2¬ são idênticos ou diferentes, e cada um representa um átomo de hidrogênio, um grupo de C~ 1-10~alquila ou similar; X representa um átomo de hidrogênio ou um átomo de flúor; Y representa -OCHR¬ 3¬R¬ 4¬ ou similar (em que R¬ 3¬ e R¬ 4¬ são idênticos ou diferentes, e cada um representa um átomo de hidrogênio, um grupo de C~ 1-10~alquila ou similar; e n representa o número inteiro 1 ou 2)!, um sal farmaceuticamente aceitável deste ou um hidrato do mesmo.
BRPI0411823-5A 2003-06-26 2004-06-25 derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlico BRPI0411823A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003181930 2003-06-26
JP2003373511 2003-10-31
JP2004128663 2004-04-23
PCT/JP2004/009398 WO2005000791A1 (ja) 2003-06-26 2004-06-25 ２－アミノ－ビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸エステル誘導体

Publications (1)

Publication Number Publication Date
BRPI0411823A true BRPI0411823A (pt) 2006-08-08

Family

ID=33556154

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411823-5A BRPI0411823A (pt) 2003-06-26 2004-06-25 derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlico

Country Status (20)

Country Link
US (5) US7960579B2 (pt)
EP (3) EP2123630B1 (pt)
JP (1) JP4792971B2 (pt)
KR (1) KR101071507B1 (pt)
AT (1) ATE487690T1 (pt)
AU (2) AU2004252017B2 (pt)
BR (1) BRPI0411823A (pt)
CA (1) CA2530706C (pt)
CY (1) CY1110997T1 (pt)
DE (1) DE602004030007D1 (pt)
DK (2) DK2123630T3 (pt)
ES (1) ES2394175T3 (pt)
HR (1) HRP20100619T1 (pt)
MX (1) MXPA05013740A (pt)
NO (1) NO335004B1 (pt)
NZ (2) NZ580554A (pt)
PL (1) PL1637517T3 (pt)
PT (1) PT1637517E (pt)
SI (1) SI1637517T1 (pt)
WO (1) WO2005000791A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960579B2 (en) * 2003-06-26 2011-06-14 Taisho Pharmaceutical Co., Ltd. 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic ester derivative
US8742161B2 (en) 2009-11-18 2014-06-03 Taisho Pharmaceutical Co., Ltd Process for producing optically active bicyclo [3.1.0] hexane derivative using enzyme
TW201124372A (en) * 2009-11-19 2011-07-16 Taisho Pharmaceutical Co Ltd Process for producing 3-alkoxy-2-amino-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid derivative and intermediate thereof
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
KR101554793B1 (ko) * 2010-11-18 2015-09-21 일라이 릴리 앤드 캄파니 mGluR 2／3 길항제로서의 4-치환된-3-벤질옥시-비시클로［3.1.0］헥산 화합물
WO2013062680A1 (en) * 2011-10-25 2013-05-02 Braincells, Inc. Novel compounds and compositions thereof for treating nervous system disorders
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
JP5983713B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸のプロドラッグを含有する医薬
FR3026843B1 (fr) * 2014-10-03 2016-11-18 Univ Pierre Et Marie Curie Paris 6 Procede de caracterisation du mecanisme de fissuration d'un materiau a partir de sa surface de rupture
RU2739318C2 (ru) 2016-04-18 2020-12-22 Тайсо Фармасьютикал Ко., Лтд. Пролекарство производного аминокислоты
JP2020506895A (ja) 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
KR101877672B1 (ko) 2017-04-03 2018-07-11 엘에스산전 주식회사 Ａｄ컨버터
EP3823604A4 (en) * 2018-07-17 2022-03-16 Board of Regents, The University of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US11501618B1 (en) * 2018-10-19 2022-11-15 Amazon Technologies, Inc. Security device with user-configurable motion detection settings
CN116444470B (zh) * 2023-03-29 2025-04-04 河南中烟工业有限责任公司 一种二羧酸二ddmp酯类化合物、制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661184A (en) * 1994-08-12 1997-08-26 Eli Lilly And Company Psychiatric agents
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
JP4194715B2 (ja) * 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
CN1247527C (zh) * 1998-08-31 2006-03-29 大正制药株式会社 6－氟双环[3.1.0]己烷衍生物
CH694053A5 (de) * 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
EP1295865A4 (en) 2000-06-28 2005-06-01 Taisho Pharmaceutical Co Ltd NEW DICARBOXYLENE DERIVATIVES
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
KR20090031962A (ko) 2001-12-27 2009-03-30 다이쇼 세이야꾸 가부시끼가이샤 6-플루오로비시클로[3.1.0]헥산 유도체
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
JP2007063129A (ja) * 2003-06-26 2007-03-15 Taisho Pharmaceut Co Ltd ２−アミノ−３−アルコキシビシクロ［３．１．０］ヘキサン誘導体
US7960579B2 (en) * 2003-06-26 2011-06-14 Taisho Pharmaceutical Co., Ltd. 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic ester derivative

Also Published As

Publication number Publication date
US20090306408A1 (en) 2009-12-10
AU2009217374A1 (en) 2009-10-08
NO335004B1 (no) 2014-08-25
PL1637517T3 (pl) 2011-04-29
EP1637517A4 (en) 2007-05-23
JPWO2005000791A1 (ja) 2006-10-19
PT1637517E (pt) 2011-01-31
US8350060B2 (en) 2013-01-08
US8258133B2 (en) 2012-09-04
SI1637517T1 (sl) 2011-01-31
ES2394175T3 (es) 2013-01-23
EP2123630A1 (en) 2009-11-25
EP1637517A1 (en) 2006-03-22
DK1637517T3 (da) 2011-01-31
US8076502B2 (en) 2011-12-13
EP2287147B1 (en) 2013-05-15
NZ580554A (en) 2011-01-28
AU2004252017B2 (en) 2009-10-08
EP1637517B1 (en) 2010-11-10
HRP20100619T1 (hr) 2011-01-31
CY1110997T1 (el) 2015-06-11
US8039647B2 (en) 2011-10-18
KR20060024817A (ko) 2006-03-17
MXPA05013740A (es) 2006-05-17
HK1095318A1 (zh) 2007-05-04
NZ544131A (en) 2009-11-27
ATE487690T1 (de) 2010-11-15
CA2530706A1 (en) 2005-01-06
US20120028982A1 (en) 2012-02-02
CA2530706C (en) 2012-11-27
US20070021394A1 (en) 2007-01-25
AU2009217374B2 (en) 2011-03-03
WO2005000791A1 (ja) 2005-01-06
JP4792971B2 (ja) 2011-10-12
US20100298561A1 (en) 2010-11-25
NO20060428L (no) 2006-03-10
US20120004232A1 (en) 2012-01-05
US7960579B2 (en) 2011-06-14
DK2123630T3 (da) 2012-10-22
EP2123630B1 (en) 2012-07-25
AU2004252017A1 (en) 2005-01-06
DE602004030007D1 (en) 2010-12-23
KR101071507B1 (ko) 2011-10-10
EP2287147A2 (en) 2011-02-23
EP2287147A3 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
BRPI0411823A (pt) derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlico
BR0317273A (pt) Utilizações farmacêuticas para ligandos alfa2delta
BRPI0415746A (pt) derivados de amida
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BR0312729A (pt) Novos derivados de indol-3-enxofre
IL188172A0 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
BR0317600A (pt) ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
BRPI0414011A (pt) naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
EP2473482B1 (en) Methods of treating orthomyxoviral infections
HUP9702241A2 (hu) 2-Amino-indán-származékok és az ezeket tartalmazó gyógyszerkészítmények
RU2017115726A (ru) Ингибиторы лизин-специфичного гингипаина
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
IL192287A0 (en) Pharmaceutical compositions and methods for use
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
BR0317289A (pt) Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico
ATE160143T1 (de) 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten
DE60112725D1 (de) Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors
BR0010961A (pt) Composto, composição farmacêutica, e, métodos para tratar epilepsia, ataques de tontura, hipocinésia, e distúrbios cranianos, distúrbios neurodegenerativos, depressão, ansiedade, pânico, dor, distúrbios neuropatológicos e distúrbios do sono
AR037711A1 (es) Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen
UY28119A1 (es) Nuevos derivados que contienen fosforo
Ramstedt et al. Methods of treating orthomyxoviral infections
BRPI0515767A (pt) método eficiente para preparação de (s)-3-[(1-dimetilamino) etil] - fenil-n-etil-n-metil-carbamato

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2312 DE 28-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.